Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2018

View Archived Issues

Stemline Therapeutics initiates rolling BLA submission for SL-401

Iontas to collaborate with Igem to identify novel IgE antibodies

Sapience Therapeutics and University of Bath enter oncology drug discovery collaboration

Biomarker of EMT linked to progression and prognosis in esophageal adenocarcinoma

Researchers present phase I data on hESC-RPE patch in age-related macular degeneration

Guangzhou Bainifu Biotech patents chimeric antigen receptors targeting CD133

Novel phospholipase A2 inhibitors discovered at Haplogen

Sichuan Haisco Pharmaceutical divulges new CACNA2D1 ligands

ImmunoPrecise Antibodies completes acquisition of ModiQuest Research

EyeGate completes enrollment in phase III study of EGP-437

PIAS1 inhibition may enhance radiotherapy for breast cancer

FunPep enters option agreement on antibody-inducing peptides with Sumitomo Dainippon Pharma

Pivotal phase III ECHO-301/KEYNOTE-252 study of epacadostat does not meet primary endpoint

Protocadherin-23 tied to adverse prognostic factors in breast cancer

FDA accepts NDA for duvelisib

FDA grants approval for Rubraca as maintenance treatment of recurrent ovarian cancer

Bayer enrolling participants in phase I trial of BAY-2402234

DGKB biomarker tied to antipsychotic therapy-induced weight gain

Enrollment ongoing in phase I trial of NGM-120

Recordati acquires rights to Cystagon

Phase II ATOMIK study of serlopitant does not meet primary or key secondary efficacy endpoints

Phase II study of FP-101 recruiting participants

Servier enters agreement with and Scandicure to conduct research in the field of metabolic diseases

AH10-7 is an improved immunotherapeutic activator of invariant natural killer T cells

Takara Bio and Otsuka to codevelop NY-ESO-1 siTCR and CD19 CAR gene therapy

FDA approves sNDA for Exparel as a nerve block to produce regional analgesia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...